A targeted multi-stage theranostic platform for immunology

Asad Moten
Uniformed Services University of the Health Sciences, USA

Cancer vaccine often suffers from poor clinical efficacy due to the nature of antigen, vaccine formulation, and unfavorable tumor microenvironment. Here we report the development of a porous silicon microparticle (PSM)-based nanovaccine that induces tumor stromal changes and strong antitumor immunity in treating HER2 positive breast cancer. This HER2 nanovaccine elicited substantially increased intra-tumor MHCII expression, induced abundant CD11c+ cell infiltration, and produced robust antitumor immunity against established HER2 positive mammary gland tumors in a CD8+ T cell-dependent manner. It also inhibited spontaneous tumor development in Balb-neuT transgenic mice. Using ovalbumin (OVA) as a model antigen, we found that the nanovector-delivered OVA was preferentially enriched into early endosome and presented to T cells in a TAP-dependent fashion. Consequently, it elicited much stronger CD8+ T cell responses than soluble OVA. Taken together, PSM delivery of vaccination as well as utility in disease analysis provided an effective approach for producing strong anti-tumor immunity by promoting innate immune cell infiltration and transforming the tumor tissue from an otherwise immunosuppressive to an immunostimulating microenvironment.

aimoten@gmail.com

Notes: